Ajinomoto Co., Inc.
22
0
1
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
4.5%
1 terminated/withdrawn out of 22 trials
93.8%
+7.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Effect of Umami Exposure on MSG Induced-satiation
Role: collaborator
Energy Reduction and Umami
Role: collaborator
Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy
Role: collaborator
Evaluation of Low Phenylalanine Formulas
Role: lead
Effect of Amino Acid on Muscle Damage
Role: collaborator
Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes
Role: collaborator
Protein Requirements for Active Adolescent Females
Role: collaborator
Protein Requirements In Active Populations
Role: collaborator
The Impact of Protein Intake on Protein Metabolism During Intensified Training
Role: collaborator
Protein Requirements for Active Children
Role: collaborator
Protein Requirements for Active Adolescent Males (IAAO-AM)
Role: collaborator
School Lunch Program (SLP) Towards Nutrition Knowledge, Attitude, Practices and Nutrition Status of Adolescents
Role: collaborator
A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology
Role: collaborator
Biomarkers for Gynecologic Cancer
Role: lead
Protein Requirements In Active Female Populations
Role: collaborator
Non- Essential Amino Acid Requirements and Metabolism in Humans
Role: collaborator
Calorie Restriction With Leucine Supplementation
Role: collaborator
Protein Requirements in Endurance-trained Athlete
Role: collaborator
Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects
Role: collaborator
Monosodium L-glutamate (MSG) on Satiety
Role: lead